ReviewInternational journal of molecular sciences2018
Extracellular Vesicles in Bladder Cancer: Biomarkers and Beyond.
Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 37 citations in OpenAlex.
- Bacillus Calmette-Guérin immunotherapy-induced extracellular vesicles promote antitumor immunity in bladder cancer.Frontiers in immunology · 2026Article
- From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer.Frontiers in immunology · 2026Review
- Role of the tumor microenvironment in promoting treatment resistance in urothelial carcinoma (Review).Molecular medicine reports · 2025Review
- Article
- Intervention of machine learning in bladder cancer research using multi-omics datasets: systematic review on biomarker identification.Discover oncology · 2025Review
- Potential of sonobiopsy as a novel diagnosis tool for brain cancer.Molecular therapy. Oncology · 2024Review
- Alix-normalized exosomal programmed death-ligand 1 analysis in urine enables precision monitoring of urothelial cancer.Cancer science · 2024Article
- Profiles of urinal exosomal miRNAs derived from bladder cancer.Central European journal of urology · 2024Article
- Bladder Cancer in Exosomal Perspective: Unraveling New Regulatory Mechanisms.International journal of nanomedicine · 2024Review
- Bladder cancer biomarkers: current approaches and future directions.Frontiers in oncology · 2024Review
- The Bladder Tumor Microenvironment Components That Modulate the Tumor and Impact Therapy.International journal of molecular sciences · 2023Review
- Protein Biomarker Discovery Studies on Urinary sEV Fractions Separated with UF-SEC for the First Diagnosis and Detection of Recurrence in Bladder Cancer Patients.Biomolecules · 2023Article
- Identify Potential Urine Biomarkers for Bladder Cancer Prognosis Using NGS Data Analysis and Experimental Validation.Applied biochemistry and biotechnology · 2023Article
- Applications of Exosomes in Diagnosing Muscle Invasive Bladder Cancer.Pharmaceutics · 2022Review
- Next-generation Proteomics-Based Discovery, Verification, and Validation of Urine Biomarkers for Bladder Cancer Diagnosis.Cancer research and treatment · 2022Article
- Advances in Diagnosis and Therapy for Bladder Cancer.Cancers · 2022Review
- Label-free optical redox ratio from urinary extracellular vesicles as a screening biomarker for bladder cancer.American journal of cancer research · 2022Article
- Differentially Expressed Extracellular Vesicle-Contained microRNAs before and after Transurethral Resection of Bladder Tumors.Current issues in molecular biology · 2021Article
- Review
- Proteomic analysis of urinary and tissue-exudative extracellular vesicles to discover novel bladder cancer biomarkers.Cancer science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Tumor-derived extracellular vesicles (TEVs) are membrane-bound, nanosized vesicles released by cancer cells and taken up by cells in the tumor microenvironment to modulate the molecular makeup and behavior of recipient cells. In this report, we summarize the pivotal roles of TEVs involved in bladder cancer (BC) development, progression and treatment resistance through transferring their bioactive cargos, including proteins and nucleic acids. We also report on the molecular profiling of TEV cargos derived from urine and blood of BC patients as non-invasive disease biomarkers. The current hurdles in EV research and plausible solutions are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.